Table 1.
Demographic and clinical data (n = 29)
| Clinical parameter | n(%) or mean ± SD |
| Age | |
| mean ± SD (yr) | 64.5 ± 16.8 |
| Range | 24-86 |
| Sex | |
| Men | 13 (44.8) |
| Women | 16 (55.2) |
| Main indication for ERC | |
| Cholestasis/jaundice | 16 (55.2) |
| Choledocholithiasis/dilated CBD | 5 (17.2) |
| Cholangitis | 3 (10.3) |
| SOL of papilla | 3 (10.3) |
| Unresolved pancreatitis | 2 (6.9) |
| Abdominal ultrasound results | |
| Dilated CBD | 15 (51.7) |
| Cholelithiasis | 12 (41.4) |
| Dilated intrahepatic ducts | 10 (34.5) |
| Choledocholithiasis | 3 (10.3) |
| Pancreatitis | 1 (3.4) |
| CBD width (mm) | |
| mean ± SD | 8.7 ± 3.7 |
| Range | 6-18 |
| Liver function tests, mean ± SD (range) | |
| Total bilirubin (mg/dL) | 4.5 ± 6.9 (0.3-32) |
| Direct bilirubin (mg/dL) | 3.0 ± 4.9 (0.1-23) |
| Alanine aminotransferase (U/L) | 206.5 ± 243.3 (12-895) |
| Aspartate aminotransferase (U/L) | 156.4 ± 185.6 (15-812) |
| Gamma glutamyl transpeptidase (U/L) | 369.4 ± 370.4 (13-1337) |
| Alkaline phosphatase (U/L) | 291.0 ± 371.4 (56-1893) |
ERC: Endoscopic retrograde cholangiography; CBD: Common bile duct; SOL: Space-occupying lesion.